These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from June 6 through June 12, 2024. Source: VerityData
Rorema Beheer disclosed a new position in the provider of healthcare information-technology solutions of 760,456 shares. Rorema Beheer purchased those shares from May 9 through June 3 at per share prices ranging from $8.12 to $9.25. Following the purchases, Rorema Beheer now owns an initial 5.1% stake of TruBridge’s outstanding stock, above the 5% threshold that requires it to publicly disclose further purchases or sales. Shares of TruBridge have lost roughly 3.8% so far this year.
Increases in Holdings
PL Capital Advisors increased its stake in the regional bank to 604,979 shares. PL Capital Advisors did so through the purchase of 66,542 Evans Bancorp shares from April 16 through June 4 at prices ranging from $25.65 to $27.75 each. Following the purchases, PL Capital now owns 11% of Evans Bancorp’s outstanding stock. Shares of Evans have lost roughly 18% year to date.
Rubric Capital Management increased its stake in the consumer and entertainment technology company to 4,143,744 shares. Rubric Capital did so through the purchase of 100,000 Xperi shares on June 10 at prices ranging from $7.55 to $8.05 each. Following the purchases, Rubric Capital continues to own 9.2% of Xperi’s outstanding stock. Shares of Xperi have lost roughly 30.4% year to date.
Fund 1 Investments increased its stake in the apparel retailer to 2,234,281 shares. Fund 1 purchased 115,262 Citi Trends shares from May 31 through June 7 at prices ranging from $22.58 to $25.55 each. Following the latest purchases, Fund 1 now owns 26.2% of Citi Trends’ outstanding stock. Shares of Citi Trends have lost roughly 21.5% so far this year.
Advertisement – Scroll to Continue
Decreases in Holdings
Avalon Ventures XI reduced its stake in the clinical-stage biopharmaceutical company to 7,304,490 shares. Avalon Ventures and its affiliates sold 1,500,000 Janux shares in a series of block trades on June 3 at prices ranging from $54.75 to $55.07. Following the sales, Avalon Ventures continues to own roughly 14.1% of Janux Therapeutics’ outstanding stock. Shares of Janux Therapeutics have nearly tripled in price so far this year.
Logos Global Management lowered its stake in the clinical-stage biopharmaceutical company to 3,233,875 shares. Logos Global sold 1,175,000 Olema Pharmaceuticals shares through two affiliates on June 4 at a price of $14.85 each. Following the sales, Logos Global continues to own approximately 5.8% of Olema Pharmaceuticals’ outstanding stock. Shares of Olema have lost roughly 1.2% so far this year.
Email: editors@barrons.com